TCON Overview

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Company’s clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.

Wall Street analysts forecast TCON stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TCON is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

TRACON Pharmaceuticals Inc revenue for the last quarter amounts to 55.00K USD, decreased -99.39 % YoY.

TRACON Pharmaceuticals Inc. EPS for the last quarter amounts to -0.94 USD, increased 370.00 % YoY.

TRACON Pharmaceuticals Inc (TCON) has 17 emplpoyees as of January 17 2026.

Today TCON has the market capitalization of 3.83M USD.